Khan, Asima
Kanpurwala, Muhammad Adnan
Khan, Riasat Ali
Mahmudi, Najum F.
Lohano, Verumal
Ahmed, Shakeel
Khan, Majid
Uddin, Fareed
Ali, Syed Mohammad
Saghir, Maliha
Baqar Abidi, Syed Hussain
Kamal, Jahanzeb
Funding for this research was provided by:
GETZ PHARMA PVT. LTD. (2128)
Article History
Received: 9 August 2023
Accepted: 17 October 2023
First Online: 8 November 2023
Declarations
:
: Authors, including Mohammad Ali, Maliha Saghir, Syed Hussain Baqar Abidi & Jahanzeb Kamal, are employees of Getz Pharma, and all other authors have no interests to declare. The therapeutic agents Treviamet® & Treviamet XR® (Sitagliptin with Metformin) used in the present study were supplied by Getz Pharma.
: The study protocol (Ref No. MN/890/LSQ/12) was approved by the Committee on Ethics of the Pakistan Medical Association, in adherence to the principles stated in the Declaration of Helsinki. Every patient was provided with comprehensive information about the objectives and duration of the study, and written informed consent was obtained from each of them.
: Not Applicable.
: Authors, including Mohammad Ali, Maliha Saghir, Syed Hussain Baqar Abidi & Jahanzeb Kamal, are employees of Getz Pharma, and all other authors have no interests to declare. The therapeutic agents Treviamet® & Treviamet XR® (Sitagliptin with Metformin) used in the present study were supplied by Getz Pharma.